micro-community-banner
 
  • Saved
Smith-Magenis Syndrome - PubMed

Smith-Magenis Syndrome - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/20301487/

SMS is an autosomal dominant disorder typically caused by a de novo deletion of chromosome 17p11.2 that includes RAI1 or an intragenic RAI1 pathogenic variant. Almost all individuals reported to...

Smith-Magenis syndrome involves distinct facial features, intellectual disability, behavioral challenges, and sleep issues. Diagnosis requires RAI1 gene analysis. Management includes therapies, medication, surveillance, and genetic counseling for recurrence risk.

  • Saved
Effectiveness of herbs taken concurrently with antihypertensive drugs in managing hypertension and lipid outcomes. A systematic review and meta-analysis - PubMed

Effectiveness of herbs taken concurrently with antihypertensive drugs in managing hypertension and lipid outcomes. A systematic review and meta-analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38830450/

The complemented herbs with antihypertensive drugs did show improvement in overall blood pressure management in the majority of the studies compared to the placebo group. Blood pressure and lipid profiles...

This review found that complementing antihypertensive drugs with herbs significantly reduced systolic blood pressure and triglycerides, though not other lipid markers, despite high heterogeneity and some study biases.

  • Saved
New drugs for treating dyslipidemias. From small molecules to small interfering RNAs - PubMed

New drugs for treating dyslipidemias. From small molecules to small interfering RNAs - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39645293/

Despite the various therapeutic tools available, many patients do not achieve therapeutic goals, and cardiovascular diseases remain a significant cause of death in our setting. Furthermore, even in patients who...

Despite LDL-C reduction, cardiovascular risk persists. New lipid-lowering drugs targeting novel pathways—like ANGPTL3, ApoC3, and Lp(a)—are emerging, including inclisiran, siRNA, and gene-editing therapies.

  • Saved
Optimizing Dyslipidemia Management: Strategies for Effective Multidisciplinary Collaboration and ASCVD Risk Reduction

Dyslipidemia refers to abnormal levels of lipids like total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). It is a primary risk factor for atherosclerotic cardiovascular disease (ASCVD), a leading cause of global mortality. Because of its critical role in cardiovascular risk, managing dyslipidemia effectively is vital for preventing adverse outcomes.

A multidisciplinary approach is essential to managing dyslipidemia and reducing ASCVD risk. ASCVD risk factors such as dyslipidemia, diabetes, hypertension, smoking, and a sedentary lifestyle often cluster together, demanding comprehensive and collaborative care. Specialists including cardiologists, endocrinologists, nephrologists, general practitioners, and nutritionists play distinct yet interconnected roles in addressing these risks. For example, cardiologists focus on cardiovascular risk, while endocrinologists manage lipid issues linked to diabetes. General practitioners ensure holistic, continuous care, and nutritionists guide lifestyle modifications foundational to dyslipidemia management.

Multidisciplinary healthcare integrates expertise from various disciplines to optimize patient outcomes. This approach promotes effective communication, shared decision-making, and respect among team members, enhancing both care quality and patient well-being. Key models include interprofessional collaboration, leveraging the unique expertise of each team member to solve problems, as well as team-based care, emphasizing clear roles and a culture of teamwork to ensure coordinated and patient-centered care.

Challenges in multidisciplinary care include coordinating efforts across specialties and maintaining seamless communication. Solutions lie in adopting digital health tools for efficient information sharing, establishing clear care pathways, and fostering a culture of mutual respect among team members.

How do you ensure seamless, patient-centered care when managing dyslipidemia across specialties? What best practices have you found for effective collaboration?

  • 7mo
    Primary prevention of cardiovascular disease is the reponsibility of all specialties but most importantly primary care clinicians In my experice nutritional changes lead to minimal changes in ldl Show More
  • 7mo
    Since EMRs don't talk well together, we often rely on the patient to let us know who's prescribing what. Communication remains poor between providers.

Show More Comments

  • Saved
A Real-World Retrospective Analysis of Secondary Prevention Patients Treated with Inclisiran over 27 Months - PubMed

A Real-World Retrospective Analysis of Secondary Prevention Patients Treated with Inclisiran over 27 Months - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40364951/

ASCVD is a global concern as it has become central to significant morbidity and mortality. LDL-C is the most important modifiable risk factor in developing ASCVD. Therefore, lowering LDL-C levels...

Inclisiran significantly reduces LDL-C (59% over 27 months) with high adherence and minimal side effects, suggesting it’s an effective long-term monotherapy or combination therapy for ASCVD risk reduction.